(S)-3,3-diphenyl-N-(1-phenylethyl)prop-2-en-1-amine | 1569818-39-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-3,3-diphenyl-N-(1-phenylethyl)prop-2-en-1-amine
• 英文别名: 3,3-diphenyl-N-[(1S)-1-phenylethyl]prop-2-en-1-amine
• CAS: 1569818-39-8
• 化学式: C₂₃H₂₃N
• 分子量: 313.442
• InChiKey: IIFWXLGWMJJOFX-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] FENDILINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE FENDILINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV TEXAS

  公开号：WO2014031755A1

  公开（公告）日：2014-02-27

  Disclosed herein are novel derivatives of fendiline, including compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives, for example, for the inhibition of K-Ras plasma membrane localization, and compositions thereof, including for the treatment of cancer, are also provided.

  本发明公开了芬地林的新的衍生物，包括具有以下通式的化合物：其中变量在本发明中定义。还提供了包含这些衍生物化合物的药物组合物、试剂盒和制品。本发明还提供了用于制造衍生物的方法和中间体，以及使用衍生物的方法，例如，用于抑制K-Ras质膜定位，以及用于治疗癌症的此类组合物。
• CALCIUM RECEPTOR-ACTIVE MOLECULES
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20130190407A1

  公开（公告）日：2013-07-25

  The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.

  本发明涉及无机离子受体在细胞和身体过程中的不同作用。 本发明的特点包括：（1）分子可以调节一个或多个无机离子受体的活性，最好是分子可以模拟或阻断细胞上的无机离子受体对细胞外离子的影响，更好的是细胞外离子是Ca2 +，其影响是在具有钙受体的细胞上; （2）无机离子受体蛋白及其片段，最好是钙受体蛋白及其片段; （3）编码无机离子受体蛋白及其片段的核酸，最好是编码钙受体蛋白及其片段的核酸; （4）针对无机离子受体蛋白的抗体及其片段，最好是钙受体蛋白; 以及（5）使用这些分子，蛋白质，核酸和抗体。
• FENDILINE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20150344407A1

  公开（公告）日：2015-12-03

  Disclosed herein are novel derivatives of fendiline, including compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives, for example, for the inhibition of K-Ras plasma membrane localization, and compositions thereof, including for the treatment of cancer, are also provided.

  本文披露了芬地林的新衍生物，包括以下化合物：其中变量在此定义。还提供了包含这些衍生物化合物的制药组合物、工具箱和制造物品。还提供了有用于制备这些衍生物的方法和中间体，以及使用这些衍生物的方法，例如用于抑制K-Ras质膜定位的方法和组合物，包括用于治疗癌症的组合物。
• Fendiline Derivatives
  申请人：The Board of Regents of the University of Texas System

  公开号：US20220177440A1

  公开（公告）日：2022-06-09

  The invention relates generally to the following novel fendiline derivatives, and the preparation and use thereof: Formula I (I) and Formula II (II)